Safety considerations in drug treatment of depression in hiv-positive patients: An updated review

Drug Safety

Volumn 34, Issue 8, 2011, Pages 623-639

  Watkins, Crystal C ^a   Pieper, Andrew A ^b   Treisman, Glenn J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Antidepressants; Antiretrovirals; Depression; Drug interactions; HIV infections; Major depressive disorder

Indexed keywords

AMPRENAVIR; CITALOPRAM; DARUNAVIR; DELAVIRDINE; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; EFAVIRENZ; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NELFINAVIR; NEVIRAPINE; PAROXETINE; PSYCHOSTIMULANT AGENT; RITONAVIR; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; AKATHISIA; ANORGASMIA; ANXIETY; BEDTIME DOSAGE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPOTENCE; INSOMNIA; MAJOR DEPRESSION; MORNING DOSAGE; NAUSEA; ORTHOSTATIC HYPOTENSION; PREMATURE EJACULATION; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ANTI-HIV AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HIV SEROPOSITIVITY; HUMANS; MEDICATION ADHERENCE;

EID: 79960346970     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11592070-000000000-00000     Document Type: Review

References (151)

1. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001 Aug; 58 (8): 721-8 (Pubitemid 32717795)
2. Kilbourne AM, Justice AC, Rabeneck L, et al. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001 Dec; 54 Suppl. 1: S22-8 (Pubitemid 34019141)
3. Cysique LA, Deutsch R, Atkinson JH, et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 2007 Jan; 13 (1): 1-11 (Pubitemid 46487370)
4. Gibbie T, Hay M, Hutchison CW, et al. Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sex Health 2007 Dec; 4 (4): 227-32 (Pubitemid 350158745)
5. Lyketsos CG, Hutton H, Fishman M, et al. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS 1996 Aug; 10 (9): 1033-9 (Pubitemid 26252635)
6. Ellis RJ, Rosario D, Clifford DB, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010 May; 67 (5): 552-8
7. Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res 2002; 11 (2): 75-82 (Pubitemid 34947050)
8. Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007 May 31; 21 (9): 1175-83 (Pubitemid 46763288)
9. Journot V, Chene G, De Castro N, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS Clin Infect Dis 2006 Jun 15; 42 (12): 1790-9 (Pubitemid 43839448)
10. Alciati A, Starace F, Scaramelli B, et al. Has there been a decrease in the prevalence of mood disorders in HIVseropositive individuals since the introduction of combination therapy? Eur Psychiatry 2001 Dec; 16 (8): 491-6 (Pubitemid 34042131)
11. Ickovics JR., Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001 Mar 21; 285 (11): 1466-74 (Pubitemid 32221895)
12. Lyketsos CG, Hoover DR, Guccione M, et al. Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry 1996 Nov; 153 (11): 1430-7 (Pubitemid 26365457)
13. Lyketsos CG, Hoover DR, Guccione M. Depression and survival among HIV-infected persons. JAMA 1996 Jan 3; 275 (1): 35-6
14. Hughes J, Jelsma J, Maclean E, et al. The health-related quality of life of people living with HIV/AIDS. Disabil Rehabil 2004 Mar 18; 26 (6): 371-6 (Pubitemid 38461187)
15. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. GenHosp Psychiatry 2002 Jan-Feb; 24 (1): 43-7 (Pubitemid 34113731)
16. Patterson K, Young C, Woods SP, et al. Screening for major depression in persons with HIV infection: the concurrent predictive validity of the Profile of Mood States Depression-Dejection Scale. Int J Methods Psychiatr Res 2006 Jun; 15 (2): 75-82 (Pubitemid 47046991)
17. Marwick KF, Kaaya SF. Prevalence of depression and anxiety disorders in HIV-positive outpatients in rural Tanzania. AIDS Care 2010 Apr; 22 (4): 415-9
18. Lyketsos CG, Hanson A, Fishman M, et al. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med 1994; 24 (2): 103-13 (Pubitemid 24253677)
19. Lenz G, Demal U. Quality of life in depression and anxiety disorders: an exploratory follow-up study after intensive inpatient cognitive behaviour therapy. Psychopathology 2000 Nov-Dec; 33 (6): 297-302
20. Meltzer-Brody S, Davidson JR. Completeness of response and quality of life in mood and anxiety disorders. Depress Anxiety 2000; 12 Suppl. 1: 95-101
21. Azar MM, Springer SA, Meyer JP, et al. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend 2010 Dec 1; 112 (3): 173-93
22. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence andmedical treatment outcomes: ameta-analysis. Med Care 2002 Sep; 40 (9): 794-811
23. Holmes J, House A. Psychiatric illness predicts poor outcome after surgery for hip fracture: a prospective cohort study. Psychol Med 2000 Jul; 30 (4): 921-9 (Pubitemid 30623977)
24. Plummer ML, Watson-Jones D, Lees S, et al. A qualitative study of participant adherence in a randomized controlled trial of herpes suppressive therapy for HIV prevention in Tanzania. AIDS Care 2010 Apr; 22 (4): 499-508
25. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999 Oct; 29 (4): 824-30 (Pubitemid 30256376)
26. Vedhara K, Schifitto G, McDermott M. Disease progression in HIV-positive women with moderate to severe immunosuppression: the role of depression. Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Behav Med 1999; 25 (1): 43-7 (Pubitemid 29184894)
27. Rabkin JG, Williams JB, Remien RH, et al. Depression, distress, lymphocyte subsets, and human immunodeficiency virus symptoms on two occasions in HIVpositive homosexual men. Arch Gen Psychiatry 1991; 48 (2): 111-9
28. Leserman J, Petitto J, Gu H, et al. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med 2002; 32 (6): 1059-73
29. Leserman J. HIV disease progression: depression, stress, and possiblemechanisms. Biol Psychiatry 2003 Aug 1; 54 (3): 295-306
30. Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med 2008 Jun; 70 (5): 539-45
31. Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIVpositive women.AmJ PublicHealth 2004 Jul; 94 (7): 1133-40
32. Riley ED, Wu AW, Perry S, et al. Depression and drug use impact health status among marginally housed HIVinfected individuals. AIDS Patient Care STDS 2003 Aug; 17 (8): 401-6 (Pubitemid 37034255)
33. Cooperman NA, Simoni JM. Suicidal ideation and attempted suicide among women living with HIV/AIDS. J Behav Med 2005 Apr; 28 (2): 149-56 (Pubitemid 40674974)
34. Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav 2003 Jun; 7 (2): 101-8 (Pubitemid 36781505)
35. Carrico AW, Antoni MH, Duran RE, et al. Reductions in depressed mood and denial coping during cognitive behavioral stress management with HIV-positive gay men treated with HAART. Ann Behav Med 2006 Apr; 31 (2): 155-64
36. Carrico AW, Johnson MO, Moskowitz JT, et al. Affect regulation, stimulant use, and viral load among HIVpositive persons on anti-retroviral therapy. Psychosom Med 2007 Nov; 69 (8): 785-92 (Pubitemid 350287486)
37. Alciati A, Gallo L, Monforte AD, et al. Major depressionrelated immunological changes and combination antiretroviral therapy in HIV-seropositive patients. Hum Psychopharmacol 2007 Jan; 22 (1): 33-40 (Pubitemid 46178776)
38. van der Lee MJ, Blenke AA, Rongen GA, et al. Interaction study of the combined use of paroxetine and fosamprenavirritonavir in healthy subjects. Antimicrob Agents Chemother 2007 Nov; 51 (11): 4098-104 (Pubitemid 350057810)
39. Sledjeski EM, Delahanty DL, Bogart LM. Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV. AIDS Patient Care STDS 2005 Nov; 19 (11): 728-36 (Pubitemid 41705169)
40. van Servellen G, Chang B, Garcia L, et al. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS 2002 Jun; 16 (6): 269-81 (Pubitemid 34620335)
41. Pieper AA, Treisman GJ. Drug treatment of depression in HIV-positive patients: safety considerations. Drug Saf 2005; 28 (9): 753-62 (Pubitemid 41428550)
42. Angelino AF, Treisman GJ. Issues in co-morbid severe mental illnesses in HIV infected individuals. Int Rev Psychiatry 2008 Feb; 20 (1): 95-101 (Pubitemid 351196204)
43. Rourke SB, Halman MH, Bassel C. Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. J Clin Exp Neuropsychol 1999; 21 (6): 737-56
44. Millikin CP, Rourke SB, Halman MH, et al. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol 2003; 25 (2): 201-15 (Pubitemid 36459568)
45. Goroll AH, Mulley AG. Primary care medicine: office evaluation and management of the adult patient. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2009
46. US Department of Health & Human Services, Agency for Healthcare Research and Quality. Guideline summary [online]. Available from URL: http://www.guideline.gov/ content.aspx?id=12811 [Accessed 2011 May 31]
47. Fekete E, Geaghan TR, Druley JA. Affective and behavioural reactions to positive and negative health-related social control in HIV+ men. Psychol Health 2009; 24 (5): 501-15
48. Hudson JI, Mangweth B, Pope Jr. HG, et al. Family study of affective spectrum disorder. Arch Gen Psychiatry 2003; 60: 170-7 (Pubitemid 36173123)
49. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. American Psychiatric Association; 2000
50. Freudenreich O, Goforth HW, Cozza KL, et al. Psychiatric treatment of persons with HIV/AIDS: an HIV-psychiatry consensus survey of current practices. Psychosomatics 2010 Nov; 51 (6): 480-8
51. Bogdanova Y, Diaz-SantosM, Cronin-Golomb A. Neurocognitive correlates of alexithymia in asymptomatic individuals with HIV. Neuropsychologia 2010 Apr; 48 (5): 1295-304
52. Paul RH, Brickman AM, Navia B, et al. Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. JNeuropsychiatry Clin Neurosci 2005; 17 (2): 167-71 (Pubitemid 41350602)
53. Tsao JC, Dobalian A, Naliboff BD. Panic disorder and pain in a national sample of persons living with HIV. Pain 2004; 109 (1-2): 172-80 (Pubitemid 38479783)
54. Ginzburg K, Butler LD, Giese-Davis J, et al. Shame, guilt, and posttraumatic stress disorder in adult survivors of childhood sexual abuse at risk for human immunodeficiency virus: outcomes of a randomized clinical trial of group psychotherapy treatment. J Nerv Ment Dis 2009; 197 (7): 536-42
55. Jong E, Oudhoff LA, Epskamp C, et al. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS 2010 Jun 19; 24 (10): 1387-405
56. Castellon SA, Hardy DJ, Hinkin CH, et al. Components of depression in HIV-1 infection: their differential relationship to neurocognitive performance. J Clin Exp Neuropsychol 2006 Apr; 28 (3): 420-37
57. Pugh K, Riccio M, Jadresic D, et al. A longitudinal study of the neuropsychiatric consequences of HIV-1 infection in gay men: II. Psychological and health status at baseline and at 12-month follow-up. Psychol Med 1994 Nov; 24 (4): 897-904
58. Beck AT, Ward C, Mendelson M. Beck depression inventory (BDI). Arch Gen Psychiatry 1961; 4: 561-71
59. Goldberg DP. General health questionnaire (GHQ-12). Windsor: NFER-Nelson, 1992
60. Treisman G, Fishman M, Lyketsos C, et al. Evaluation and treatment of psychiatric disorders associated with HIV infection. Res Publ Assoc Res NervMent Dis 1994; 72: 239-50
61. Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001; 61 (1): 81-110 (Pubitemid 32108326)
62. Grassi L, Mondardini D, Pavanati M, et al. Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. J Affect Disord 2001 May; 64 (2-3): 195-202 (Pubitemid 32324212)
63. Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994 Apr; 151 (4): 516-23 (Pubitemid 24115815)
64. De Wit S, Cremers L, Hirsch D, et al. Efficacy and safety of trazodone versus clorazepate in the treatment of HIVpositive subjects with adjustment disorders: a pilot study. J Int Med Res 1999 Sep-Oct; 27 (5): 223-32 (Pubitemid 30064250)
65. Kristiansen JE, Hansen JB. Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia. Int J Antimicrob Agents 2000 Apr; 14 (3): 209-13 (Pubitemid 30201545)
66. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials 2005 Jul-Aug; 6 (4): 187-96 (Pubitemid 41601130)
67. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA 2001 Dec 12; 286 (22): 2857-64 (Pubitemid 33126929)
68. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999 Jan; 156 (1): 101-7 (Pubitemid 29034886)
69. Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry 1994 Mar; 55 (3): 92-7 (Pubitemid 24116434)
70. Sherr L, Harding R, Lampe F, et al. Clinical and behavioural aspects of aging with HIV infection. Psychol Health Med 2009 May; 14 (3): 273-9
71. Omonuwa TS, Goforth HW, Preudhomme X, et al. The pharmacologic management of insomnia in patients with HIV. J Clin Sleep Med 2009 Jun 15; 5 (3): 251-62
72. Letendre SL, Ellis RJ, Ances BM, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med 2007 Apr-May; 18 (2): 45-55
73. Maina G, Albert U, Salvi V, et al. Weight gain during longterm treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004 Oct; 65 (10): 1365-71
74. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010 Oct; 71 (10): 1259-72
75. Daly EJ, Trivedi MH, Fava M, et al. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. J Clin Psychopharmacol 2011 Feb; 31 (1): 31-8
76. Purcell DW, Wolitski RJ, Hoff CC, et al. Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men. AIDS 2005 Apr; 19 Suppl. 1: S57-66
77. Richardson D, Goldmeier D. Pharmacological treatment for premature ejaculation. Int J STDAIDS 2005Oct; 16 (10): 709-11
78. Woodrum ST, Brown CS. Management of SSRI-induced sexual dysfunction. Ann Pharmacother 1998 Nov; 32 (11): 1209-15 (Pubitemid 28543468)
79. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005 Aug; 66 (8): 974-81 (Pubitemid 41191788)
80. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006 Sep; 40 (9): 1618-22 (Pubitemid 44330206)
81. Arinzon ZH, Lehman YA, Fidelman ZG, et al. Delayed recurrent SIADH associated with SSRIs. Ann Pharmacother 2002 Jul-Aug; 36 (7-8): 1175-7 (Pubitemid 34755794)
82. Rabkin JG, Wagner GJ, McElhiney MC, et al. Testosterone versus fluoxetine for depression and fatigue in HIV/ AIDS: a placebo-controlled trial. J Clin Psychopharmacol 2004 Aug; 24 (4): 379-85 (Pubitemid 38944135)
83. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a metaanalysis. Curr Med Res Opin 2009 Jan; 25 (1): 161-75
84. Evans DL, Lynch KG, Benton T, et al. Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome. Biol Psychiatry 2008 May 1; 63 (9): 899-905 (Pubitemid 351458446)
85. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008 Feb 15; 63 (4): 424-34
86. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010 Sep; 17 (9): 1113-e88
87. Thompson A, Silverman B, Dzeng L, et al. Psychotropic medications and HIV. Clin Infect Dis 2006 May 1; 42 (9): 1305-10
88. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 1997 Jun; 16 (6): 374-90 (Pubitemid 27326045)
89. Marcus M, Maida CA, Freed JR., et al. Oral white patches in a national sample of medical HIV patients in the era of HAART. Community Dent Oral Epidemiol 2005 Apr; 33 (2): 99-106 (Pubitemid 41577046)
90. Marcus M, Yamamoto JM, Der-Martirosian C, et al. National estimates of out-of-pocket dental costs for HIVinfected users of medical care. J Am Dent Assoc 2005 Oct; 136 (10): 1406-14 (Pubitemid 41494533)
91. von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 1998 Oct; 87 (10): 1184-9 (Pubitemid 28455606)
92. Lanzafame M, Ferrari S, Lattuada E, et al. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez Med 2009 Mar; 17 (1): 35-7
93. Elliott AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000 Apr; 20 (2): 265-7 (Pubitemid 30202373)
94. Markoula S, Konitsiotis S, Chatzistefanidis D, et al. Akathisia induced by mirtazapine after 20 years of continuous treatment. Clin Neuropharmacol 2010 Jan-Feb; 33 (1): 50-1
95. Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Ann Pharmacother 2008 Jun; 42 (6): 841-6 (Pubitemid 351778091)
96. Poyurovsky M, Pashinian A, Weizman R, et al. Low-dose mirtazapine: a new option in the treatment of antipsychotic- induced akathisia: a randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006 Jun 1; 59 (11): 1071-7 (Pubitemid 43849656)
97. Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009 Feb; 66 (2): 255-8
98. Elliott AJ, Russo J, Bergam K, et al. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999 Apr; 60 (4): 226-31 (Pubitemid 29193919)
99. Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003 Oct 15; 54 (8): 800-5 (Pubitemid 37205131)
100. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000 Oct; 295 (1): 321-7
101. Hesse LM, von Moltke LL, Shader RI, et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001 Feb; 29 (2): 100-2 (Pubitemid 32112922)
102. Robertson SM, Maldarelli F, Natarajan V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008 Dec 15; 49 (5): 513-9
103. Lavrut T, Garraffo R, Ferrando S, et al. Effect of tipranavir/ ritonavir treatment on the steady-state pharmacokinetics of bupropion in healthy volunteers [abstract no. P4.3/03]. 11th European AIDS Conference; 2007Oct 24-27; Madrid
104. Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25 (2): 91-110 (Pubitemid 34261185)
105. Ahern TH, Javors MA, Eagles DA, et al. The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice. Neuropsychopharmacology 2006 Apr; 31 (4): 730-8
106. GlaxoSmithKline. Wellbutrin XL- prescribing information [online]. Available from URL: http://us.gsk.com/ products/assets/us-wellbutrinXL.pdf [Accessed 2011 May 31]
107. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med 2010 Dec; 77 (12): 859-82
108. Schifitto G, Yiannoutsos CT, Ernst T, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology 2009 Dec 8; 73 (23): 1975-81
109. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007 Sep 25; 69 (13): 1314-21 (Pubitemid 47482445)
110. Evans SR, Yeh TM, Sacktor N, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 2007 Nov-Dec; 8 (6): 437-46 (Pubitemid 350305218)
111. Sacktor N, Schifitto G, McDermott MP, et al. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000 Jan 11; 54 (1): 233-5 (Pubitemid 30038769)
112. Koutsilieri E, Scheller C, Sopper S, et al. Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection. Eur J Pharmacol 2001 Jan 5; 411 (1-2): R1-2 (Pubitemid 32013130)
113. Koutsilieri E, Sopper S, Scheller C, et al. Involvement of dopamine in the progression of AIDS dementia complex. J Neural Transm 2002b Mar; 109 (3): 399-410 (Pubitemid 34251642)
114. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000 Jun; 61 (6): 436-40 (Pubitemid 30452211)
115. Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV/AIDS: a randomized placebocontrolled study. J Clin Psychiatry 2010 Jun; 71 (6): 707-15
116. McElhiney M, Rabkin J, Van Gorp W, et al. Modafinil effects on cognitive function in HIV+ patients treated for fatigue: a placebo controlled study. J Clin Exp Neuropsychol 2010 Jun; 32 (5): 474-80
117. McElhiney MC, Rabkin JG, Rabkin R, et al. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am J Drug Alcohol Abuse 2009; 35 (1): 34-7
118. Breitbart W, Rosenfeld B, Kaim M, et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001 Feb 12; 161 (3): 411-20 (Pubitemid 32116559)
119. Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry 2004 Dec; 65 (12): 1688-95
120. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001 Jan; 158 (1): 131-4 (Pubitemid 32047260)
121. Schifitto G, Zhong J, Gill D, et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol 2009 Apr; 15 (2): 176-86
122. Letendre SL, Woods SP, Ellis RJ, et al. Lithium improves HIV-associated neurocognitive impairment. AIDS 2006 Sep 11; 20 (14): 1885-8 (Pubitemid 44358907)
123. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983 Dec; 40 (12): 1335-42 (Pubitemid 14201213)
124. Nierenberg AA, Price LH, Charney DS, et al. After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 1990 Mar; 18 (3): 167-75 (Pubitemid 20069891)
125. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic- resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993 May; 162: 634-40 (Pubitemid 23150996)
126. Ogura C, Okuma T, Uchida Y, et al. Combined thyroid (triiodothyronine)- tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974; 28 (3): 179-86
127. Perry EB, Berman RM, Sanacora G, et al. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry 2004 Feb; 65 (2): 238-43
128. Sheehan NL, Brouillette MJ, Delisle MS, et al. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother 2006 Jan; 40 (1): 147-50 (Pubitemid 43221489)
129. Berman RM, Anand A, Cappiello A, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebocontrolled trial. Biol Psychiatry 1999 May 1; 45 (9): 1170-7 (Pubitemid 29236558)
130. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009 Apr; 14 (4): 197-206
131. Ances BM, Letendre SL, Alexander T, et al. Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. Int Rev Psychiatry 2008 Feb; 20 (1): 89-93 (Pubitemid 351196200)
132. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993 May; 50 (5): 387-93 (Pubitemid 23143128)
133. Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61 Suppl. 2: 13-9 (Pubitemid 30131898)
134. Bates DE, Herman RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann Pharmacother 2006 Jun; 40 (6): 1190-5 (Pubitemid 43886980)
135. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007 Dec; 116 (3): 496-526 (Pubitemid 350116943)
136. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2002 Jun 14; 16 (9): 1201-15 (Pubitemid 34666654)
137. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003 Apr; 25 (4): 1200-10 (Pubitemid 36532587)
138. Ouellet D, Hsu A, Qian J, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998 Dec; 42 (12): 3107-12 (Pubitemid 28553726)
139. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Shortterm exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003 Apr; 43 (4): 414-22 (Pubitemid 36368783)
140. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008 Jul; 42 (7): 1048-59
141. McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 2010 Jun 1; 24 (9): 1367-70
142. Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009 Aug; 21 (8): 976-83
143. Treisman G, Angelino A. Interrelation between psychiatric disorders and the prevention and treatment of HIV infection. Clin Infect Dis 2007 Dec 15; 45 Suppl. 4: S313-7 (Pubitemid 351417235)
144. Carvalho FC, Barbi MS, Sarmento VH, et al. Surfactant systems for nasal zidovudine delivery: structural, rheological and mucoadhesive properties. J Pharm Pharmacol 2010 Apr; 62 (4): 430-9
145. JenaA, SachdevaRK, SharmaA, et al.Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic) 2009 Sep-Oct; 8 (5): 318-22
146. Maxwell S, Scheftner WA, Kessler HA, et al. Manic syndrome associated with zidovudine treatment. JAMA 1988 Jun 17; 259 (23): 3406-7
147. Cruess DG, Evans DL, Repetto MJ, et al. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003 Aug 1; 54 (3): 307-16 (Pubitemid 37267860)
148. Gutierrez-Valencia A, Viciana P, Palacios R, et al. Steppeddose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med 2009 Aug 4; 151 (3): 149-56
149. Arendt G, de Nocker D, von Giesen HJ, et al. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007 Mar; 6 (2): 147-54 (Pubitemid 46380808)
150. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001 Jan 5; 15 (1): 71-5 (Pubitemid 32055781)
151. DiGiacinto JL, Chan-Tack KM, Robertson SM, et al. Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin. J Clin Pharmacol 2008 Apr; 48 (4): 518-23 (Pubitemid 351389117)